Sanofi (Sanofi) Interest Expense

: $-716 Mil (TTM As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sanofi's interest expense for the six months ended in Jun. 2023 was $ -401 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-716 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sanofi's Operating Income for the six months ended in Jun. 2023 was $ 5,399 Mil. Sanofi's Interest Expense for the six months ended in Jun. 2023 was $ -401 Mil. Sanofi's Interest Coverage for the quarter that ended in Jun. 2023 was 13.47. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sanofi Interest Expense Historical Data

The historical data trend for Sanofi's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-516.67

-527.98

-439.55

-488.35

-718.65

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense																-227.12	-216.70	-271.19	-400.87	-315.16

Sanofi Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-716 Mil.

Sanofi (NAS:SNY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sanofi's Interest Expense for the six months ended in Jun. 2023 was $-401 Mil. Its Operating Income for the six months ended in Jun. 2023 was $5,399 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was $17,421 Mil.

Sanofi's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2023 )	/	Interest Expense (Q: Jun. 2023 )
	=	-1	*	5398.7	/	-400.867
	=	13.47

The higher the ratio, the stronger the company's financial strength is.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.